Milven (Venlafaxine)

Venlafaxine, the active ingredient in Milven, is a Serotonin‑Norepinephrine Reuptake Inhibitor (SNRI) presented as an oral tablet for oral administration. It is prescribed for the treatment of major depressive disorder and several anxiety disorders in adult patients. The medication works by modulating neurotransmitter levels, helping to improve mood and reduce anxiety symptoms.

GNH USA supplies Milven as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide through its established distribution network, ensuring product quality and regulatory compliance to meet local market requirements.

Venlafaxine is an SNRI indicated for several mood and anxiety disorders. - Major depressive disorder: reduces depressive symptoms and improves overall mood. - Generalized anxiety disorder: lessens excessive worry and physical tension. - Social anxiety disorder: decreases fear of social situations and improves functioning. - Panic disorder: lowers frequency and intensity of panic attacks.

Venlafaxine may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Headache: transient cranial pain. - Dry mouth: reduced salivation. - Insomnia: difficulty falling or staying asleep. - Dizziness: light‑headed sensation. - Sweating: increased perspiration.

Serious or Rare Side Effects: - Suicidal thoughts: emergence of new or worsening ideation. - Serotonin syndrome: potentially life‑threatening condition with agitation, hyperthermia, and neuromuscular abnormalities. - Severe hypertension: marked increase in blood pressure. - Hyponatremia: low sodium levels, especially in elderly patients. - Cardiac arrhythmia: abnormal heart rhythm. - Hepatic injury: signs of liver dysfunction.

Before initiating therapy, clinicians should consider several safety measures. - Assess cardiovascular status: monitor blood pressure and heart rate before and during treatment. - Screen for bipolar disorder: risk of mood switching to mania. - Avoid abrupt discontinuation: taper under medical supervision to reduce withdrawal symptoms. - Use caution in hepatic impairment: dose adjustment may be required. - Pregnancy and lactation: discuss potential risks with the prescriber. - Store at ambient temperature: keep in the original container, protect from moisture and light.

Venlafaxine can interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of serotonin syndrome. - Linezolid or other reversible MAO inhibitors: potentiate serotonergic effects. - Tramadol: increased risk of serotonin syndrome.

Moderate Interactions (Monitor Closely): - Strong CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): may raise venlafaxine plasma levels. - Non‑steroidal anti‑inflammatory drugs (NSAIDs): heightened bleeding risk. - Antihypertensive agents: additive blood‑pressure lowering effect.